ARWR Stock Balance Sheets

Arrowhead Pharmaceuticals Quarterly Balance Sheets Chart

Quarterly

Annual

Account Receivables

Cash and Cash Eq

Account Payables

Deferred Revenue

Arrowhead Pharmaceuticals Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31

assets
current assets:
cash, cash equivalents and restricted cash	129,793,000	185,709,000	69,399,000	127,704,000	58,215,000	110,891,000	105,334,000	134,959,000	202,249,000	108,005,000
accounts receivable	9,699,000	2,365,000					1,247,000	69,434,000	39,568,000	1,410,000	239,000	1,317,000	150,000	10,255,000	671,000	955,000	9,002,000	845,673	21,692,564	1,265,771	1,345,298	661,361	2,044,111	13,422,340	3,168,578	327,375	14,975	16,288	149,931	67,797	937,313	580,825
available-for-sale securities, at fair value	770,579,000	911,700,000	367,272,000	395,410,000	162,064,000	292,735,000
prepaid expenses	23,692,000	23,769,000	9,207,000	11,022,000	10,516,000	8,813,000	10,053,000	9,935,000	8,412,000	7,289,000	6,761,000	6,622,000	5,199,000	4,362,000	7,276,000	6,639,000	7,069,000	4,250,896	4,096,473	3,062,333	2,733,140	3,317,999	3,103,476	1,757,928	1,550,437	1,267,717	1,095,977	744,246	651,239	867,363	931,042	731,834	569,415	1,289,923	3,446,863	3,772,643	3,783,344	3,293,285	3,499,324	3,811,096	4,451,124	588,626	700,063	643,023													182,383	239,097	337,002	225,107
other current assets	13,160,000	11,677,000	4,184,000	7,514,000	7,104,000	7,082,000	7,162,000	14,436,000	25,188,000	20,204,000	8,892,000	7,796,000	2,795,000	2,191,000	1,696,000	1,845,000	2,318,000	1,781,691	2,411,937	2,536,284	1,534,344	2,563,435	1,492,175	1,590,195	478,310	640,117	279,049	357,989	1,604,986	1,359,638	896,150	1,747,801	3,495,369	3,771,172	1,507,470	909,561	1,903,884	823,620	654,924	327,384	62,841	48,502	538,742	633,807													18,470	114,833	68,950
total current assets	946,923,000	1,135,220,000	450,062,000	541,650,000	237,899,000	419,521,000	470,165,000	574,810,000	574,999,000	405,299,000	432,388,000	417,630,000	338,278,000	384,597,000	525,955,000	586,757,000	323,716,000	322,370,397	315,232,854	314,474,173	507,614,372	265,246,817	244,538,724	234,970,345	248,950,613	78,768,598	61,870,095	92,660,460	53,106,877	67,902,904	77,902,394	89,689,923	106,230,353	90,502,543	49,601,432	66,143,493	82,283,814	102,871,161	114,687,701	120,146,953	132,164,598	154,800,770	163,422,946	161,923,165	76,411,623	28,843,719	34,410,996	3,739,881	6,063,983	6,567,336	5,903,034	8,817,561	9,173,908	9,861,174	7,048,556	8,581,382	11,040,539	8,131,775	10,125,876	2,990,470	4,148,395	2,483,555	2,754,753	4,177,568	9,020,926	10,561,117	14,541,167	20,546,627	26,208,115	25,305,428	32,105,698	22,494,196	28,806,894	28,775,791	31,342,022	36,113,460	19,518,681
property, plant and equipment	381,048,000	384,803,000	375,911,000	359,252,000	333,411,000
intangible assets	7,286,000	7,711,000	8,987,000	9,412,000	9,837,000	10,262,000	10,687,000	11,112,000	11,537,000	11,962,000	12,387,000	12,813,000	13,238,000	13,663,000	14,088,000	14,513,000	14,938,000	15,363,151	15,788,258	16,213,366	16,638,473	17,063,580	17,488,688	17,913,795	18,338,903	18,764,010	19,189,117	19,614,224	20,039,332	20,464,439	20,889,546	21,314,653	21,739,761	22,164,868	23,534,910	23,960,017	24,385,125	24,824,116	25,262,886	25,701,657	999,809	1,013,473		3,213,186
right-of-use assets	44,002,000	44,452,000	44,339,000	44,626,000	44,907,000	45,297,000	40,667,000	41,114,000	41,655,000	58,291,000	68,908,000	16,379,000	16,875,000	17,346,000		18,370,000	15,747,000	16,137,085	16,522,013	10,263,197	10,440,758
other assets	1,353,000	1,312,000	4,460,000	210,000	232,000	210,000	210,000	210,000	210,000	218,000	275,000	275,000	273,000	272,000	272,000	265,000	265,000	265,359	265,359	144,150	144,150	144,148	170,921	141,918	141,918	141,918	141,918	141,918	141,918	141,918	154,618	152,119	122,333	122,333	122,333	122,333	45,789	45,789	45,789	41,414	7,041,414	41,414	41,414	166,414
total assets	1,380,612,000	1,573,498,000	883,759,000	955,150,000	626,286,000	765,552,000	795,856,000	891,308,000	891,489,000	691,939,000	751,782,000	703,575,000	638,539,000	710,148,000	734,927,000	756,795,000	499,251,000	522,503,743	555,728,072	561,075,702	587,601,634	349,845,437	336,828,445	333,940,433	340,947,388	111,609,951	112,903,027	126,998,915	88,220,493	104,022,280	115,081,549	126,871,643	144,258,106	128,176,505	85,533,496	94,607,471	111,381,139	132,267,914	145,190,325	162,378,458	162,136,761	182,816,756	196,622,876	202,641,394	92,692,477	37,329,631	41,488,495	12,419,325	15,231,131	16,527,818	16,488,027	20,080,976	23,062,344	15,888,563	13,289,834	15,236,725	15,189,763	12,354,542	14,596,070	7,758,203	9,129,264	7,702,174	8,198,650	10,167,700	15,390,124	17,255,442	19,126,157	24,821,967	30,663,734	29,852,952	36,716,378	26,904,512	34,393,825	34,525,878	40,582,772	45,085,271	25,880,146
liabilities, noncontrolling interest and stockholders’ equity
current liabilities:
accounts payable	33,050,000	9,980,000	26,550,000	8,521,000	4,460,000	35,866,000	7,874,000	9,556,000	796,000	2,868,000	5,894,000	10,603,000	4,068,000	9,457,000	10,037,000	5,299,000	4,827,000	6,828,909	4,073,869	13,417,692	12,201,532	7,649,921	4,630,244	4,062,189	3,936,590	2,806,098	2,165,731	1,810,431	5,707,047	4,076,514	3,233,421	2,597,889	3,698,297	12,232,906	5,945,370	7,542,498	5,288,922	5,031,706	4,862,263	4,936,282	5,994,951	2,579,478	2,158,133	2,511,572	589,348	1,199,632	1,061,944	871,707	809,524	877,986	994,372	801,104	714,057	576,809	501,278	235,930	2,423,844	681,563	1,032,792	884,018	891,677	1,013,281	1,398,813	2,001,827	1,911,489	1,342,000	1,083,560	1,160,510						846,580			490,892
accrued expenses	64,818,000	78,450,000	47,899,000	37,055,000	46,604,000	39,763,000	38,191,000	39,551,000	48,174,000	46,856,000	32,499,000	23,710,000	18,518,000	14,001,000	29,525,000	12,862,000	9,570,000	5,388,556	9,414,696	4,419,233	3,988,186	6,504,729	5,173,146	5,718,774	3,907,515	5,043,087	2,163,533	4,127,208	3,478,512	4,564,507	1,993,674	2,184,844	4,762,105	4,587,467	6,263,349	3,834,269	3,920,312	5,376,119	1,726,449	2,041,174	1,148,092	1,399,486	1,068,667	913,856	684,520	638,884	706,092	823,517	842,639	730,775	1,022,734	2,383,651	2,386,796	864,511	472,279	433,347	2,840,142	471,236	686,524	407,161	411,211	420,077	843,790	1,042,652	1,386,861	844,549	612,844	487,732	396,697	545,703	456,145	329,747	254,163	677,722	1,184,752	632,732	631,874
accrued payroll and benefits	19,298,000	16,613,000	15,795,000	13,741,000	8,777,000	17,963,000	4,434,000	5,494,000	4,094,000	12,251,000	2,648,000	3,765,000	2,968,000	9,773,000	3,648,000	2,859,000	2,753,000	8,060,854	1,991,001	1,616,090	2,993,682	4,955,887	1,427,855	967,674	1,629,871	3,937,605	1,147,780	918,226	1,936,024	3,399,679	1,034,569	765,292	2,150,014	3,969,706	1,129,460	1,395,004	1,419,423	3,824,062	884,373	1,272,001	2,175,484	3,268,506	611,092	732,131	678,035		811,046	1,222,573	1,067,763	1,127,219	1,051,079	1,159,624	637,691	195,649	227,696	171,847	171,213	191,425	204,911	168,536	239,781
lease liabilities	7,010,000	6,782,000	6,053,000	5,285,000	3,421,000	10,563,000	2,823,000	2,711,000	2,664,000	2,776,000	2,883,000	2,910,000	2,826,000	2,250,000	1,290,000	1,272,000	1,183,000	1,094,777	1,011,951	688,454	461,178
deferred revenue	22,979,000	43,268,000				866,000	16,905,000	29,839,000	66,281,000	74,099,000	84,288,000	97,869,000	108,652,000	111,055,000	150,934,000	144,879,000	6,744,000	19,291,075	26,274,362	33,174,765	54,034,129	77,769,629	75,681,868	90,889,801	124,925,638	600	943,200	1,565,000	1,875,001	5,269,741	13,283,006	21,169,191	25,584,181	2,569,792	26,042	65,625	109,375	103,125	71,875	65,625	109,375	103,125	71,875	65,625	109,375	103,125	71,875	65,625	109,375	37,500	71,875	69,792	101,042																37,999	98,570	378,645					31,250	68,750
credit facility	40,000,000	65,000,000
other liabilities	7,375,000	448,000	417,000	573,000	461,000	435,000	669,000																																					1,755,520
total current liabilities	194,530,000	220,541,000	96,714,000	65,175,000	63,723,000	105,456,000	70,227,000	87,151,000	122,009,000	138,850,000	128,212,000	138,857,000	137,032,000	146,536,000	195,434,000	167,188,000	25,094,000	40,681,433	42,783,141	53,333,497	73,695,268	97,070,679	87,087,065	101,812,390	134,611,773	12,364,951	7,127,120	9,123,879	13,716,249	18,701,048	20,319,614	27,551,628	36,998,092	25,643,794	14,840,268	14,058,345	12,328,014	15,900,571	9,532,488	13,210,361	11,497,665	11,847,024	8,250,096	10,482,540	9,018,408	8,725,020	6,677,866	7,164,026	6,077,978	5,327,888	5,815,416	6,375,521	5,060,024	2,581,949	2,159,704	2,494,934	7,901,951	4,276,246	5,140,251	2,279,634	2,579,789	2,344,238	3,409,782	4,448,743	4,859,962	3,726,299	2,555,455	2,293,532	2,283,394	2,896,375	2,940,122	1,146,210	1,015,244	2,920,234	1,728,638	2,589,236	1,456,502
long-term liabilities:
lease liabilities, net of current portion	105,690,000	107,529,000	112,040,000	113,632,000	115,157,000	104,608,000	79,911,000	80,070,000	79,470,000	78,800,000	78,231,000	22,698,000	22,489,000	23,295,000	22,854,000	22,528,000	19,685,000	20,043,178	20,359,726	14,178,735	14,377,723
liability related to the sale of future royalties	360,254,000	352,276,000	336,031,000	280,938,000	273,692,000	268,326,000	263,064,000	257,906,000	252,849,000
credit facility, net of current portion	200,332,000	208,927,000
total long-term liabilities	666,276,000	668,732,000	448,071,000	394,570,000	388,849,000	372,934,000	343,644,000	339,051,000	373,108,000	134,750,000	149,393,000	112,452,000	128,947,000	154,790,000	102,603,000	144,058,000	19,685,000	20,043,178	20,359,726	14,178,735	14,377,723	8,738,506	24,071,340	31,487,807	34,835,584	4,003,999	4,016,548	4,159,954	4,304,934	4,454,070	5,219,651	5,983,526	10,051,593	7,508,452	11,268,062	6,622,889	6,684,733	6,745,709	4,913,443	4,971,743	4,929,425	4,984,477	2,564,991	2,621,297	2,763,782	2,869,822	1,504,661	1,494,795	1,548,674	2,391,021	2,224,008	2,138,769	2,253,410	742,446	560,878	519,716						500,000	574,845	3,312,886	3,530,087	1,226,534
commitments and contingencies
noncontrolling interest and stockholders’ equity:
common stock	230,000	230,000	217,000	217,000	200,000	200,000	199,000	199,000	199,000	198,000	198,000	198,000	197,000	197,000	197,000	196,000	195,000	194,746	194,620	194,117	193,481	187,876	187,577	187,035	184,961	180,875	180,224	179,940	167,287	167,155	167,142	167,142	166,782	162,116	152,799	152,330	151,997	151,914	151,868	151,805		147,026	145,278			124,859	123,676	109,402	110,420	108,354	106,086	105,582	105,306	86,423	71,849	71,822	71,822	71,735	70,953	63,929	61,511	56,428	46,220	42,950	42,950	42,950	38,954	38,778	38,728	38,622	38,605	34,245	34,241	34,156	33,829	33,814	28,016
additional paid-in capital	2,120,130,000	2,106,864,000	1,786,304,000	1,768,866,000	1,320,356,000	1,300,395,000	1,281,393,000	1,260,310,000	1,239,178,000	1,219,213,000	1,189,113,000	1,115,373,000	1,080,035,000	1,053,386,000	1,017,949,000	996,645,000	978,655,000	965,410,146	948,532,470	936,353,920	922,050,595	664,086,155	657,136,601	652,411,876	647,142,565	582,902,694	578,642,206	574,963,592	516,577,723	514,037,301	512,032,168	510,318,940	508,303,137	493,844,909	436,071,308	431,061,481	428,838,629	426,873,358	423,182,550	420,696,539	393,464,197	391,164,558	388,558,305	381,966,576	259,369,442	193,514,766	187,282,068	151,573,260	149,976,199	145,917,968	139,943,181	136,487,707	136,318,592	127,476,435	121,649,155	121,288,591	120,157,693	119,716,834	118,780,923	114,181,556	113,440,515	110,070,327	105,012,634	99,179,335	98,484,060	97,756,126	89,899,453	88,361,112	87,373,256	84,672,783	83,972,459	62,799,848	62,311,692	59,113,369	62,259,035	59,962,209	39,126,687
accumulated other comprehensive income	5,357,000	4,390,000											-108,000	-69,000	62,000	102,000	198,000	18,433	-175,219	-629,114	-195,550	-391,624	-103,078	-71,906	-43,744	-21,564	-3,338	25,265	23,704	33,232	-18,386	-30,695	-185,159	7,449	-30,712	59,913	-90,607	-136,425	-65,947	-63,965
accumulated deficit	-1,603,404,000	-1,428,163,000	-1,454,987,000	-1,284,194,000	-1,158,894,000	-1,026,030,000	-916,351,000	-813,405,000	-862,080,000	-820,755,000	-735,244,000	-663,198,000	-707,564,000	-644,692,000	-581,318,000	-551,394,000	-524,576,000	-503,844,193	-455,411,478	-441,800,265	-421,964,695	-419,290,967	-430,995,872	-451,331,581	-475,228,563	-487,265,816	-476,504,545	-460,898,527	-446,014,216	-432,815,338	-422,083,452	-416,563,710	-410,521,151	-398,435,043	-376,213,057	-356,792,315	-335,976,455	-316,712,041	-291,968,905	-276,032,853		-224,771,159	-202,340,717
stockholders’ equity	522,313,000
noncontrolling interest	-2,507,000	904,000	8,427,000	11,611,000	13,307,000	15,819,000	17,155,000	18,334,000	19,333,000	19,819,000	20,250,000								-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188	-555,188			-1,861,477	-1,821,297	-1,763,877	-1,651,001	-1,552,383	-1,370,301	-1,203,733	-916,665	-669,114	-420,232	-226,938	-56,523	136,974	-761,154	-967,406	-657,296	-399,210	-121,805
total noncontrolling interest and stockholders’ equity	519,806,000	684,225,000	338,974,000	495,405,000	173,714,000		381,985,000	465,106,000	396,372,000
total liabilities, noncontrolling interest and stockholders’ equity	1,380,612,000	1,573,498,000	883,759,000	955,150,000	626,286,000		795,856,000	891,308,000	891,489,000		751,782,000
total arrowhead pharmaceuticals, inc. stockholders’ equity		683,321,000	330,547,000	483,794,000	160,407,000		364,830,000	446,772,000	377,039,000
accumulated other comprehensive loss			-987,000	-1,095,000	-1,255,000	-3,222,000	-411,000	-332,000	-258,000	-136,000	-140,000	-107,000
held-to-maturity securities, at amortized cost
property and equipment						290,262,000	231,369,000	185,228,000	147,314,000	110,297,000	71,904,000	54,888,000	52,303,000	48,675,000	47,786,000	39,400,000	33,730,000	30,880,868	30,389,707	29,362,741	26,434,783	23,214,899	17,074,613	13,378,321	13,920,667	13,935,425	14,029,239	14,582,313	14,932,366	15,513,019	16,134,991	15,714,948	16,165,659	15,386,761	12,274,821	4,381,628	4,666,411	4,526,848	4,108,667	4,127,366	4,124,441	3,872,753	3,674,131	3,290,270	3,186,147	3,513,235	3,793,311	4,013,094	4,426,683	4,895,652	5,365,789	6,745,214	6,927,240	25,437	29,921
deferred revenue, net of current portion								1,075,000	40,789,000	55,950,000	71,162,000	89,754,000	106,458,000	131,495,000	79,749,000	121,530,000						5,035,142	22,258,994	29,732,938	33,171,402						625,000	1,250,000	5,180,115	2,500,000
noncontrolling interest and stockholders' equity:
total arrowhead pharmaceuticals, inc. stockholders' equity						271,343,000				398,520,000								461,779,132	493,140,393	494,118,658	500,083,831	244,591,440	226,225,228	201,195,424	172,055,219	95,796,189	102,314,547	114,270,270	70,754,498	81,422,350	90,097,472	93,891,677	97,763,609	95,579,447	59,980,354	74,481,425
total noncontrolling interest and stockholders' equity						287,162,000				418,339,000
total liabilities, noncontrolling interest and stockholders' equity						765,552,000				691,939,000
short term investments							346,369,000	346,046,000	299,582,000		277,057,000	192,912,000	112,537,000	56,627,000	63,924,000	79,148,000	79,394,000	86,889,751	67,709,263	50,959,058	40,969,341		48,567,215	56,560,674	53,980,307	46,400,176	32,484,708	21,736,820	39,169,376	40,769,539	36,754,754	24,910,492			1,030,556	11,160,442	14,431,498	17,539,902	23,280,640	19,561,172	23,532,402	21,653,032	23,834,408	17,798,475	15,912,757	9,030,261	4,058,003
long-term investments							42,758,000	78,834,000	115,774,000	105,872,000												44,175,993
short-term investments										268,391,000												36,899,894
marketable securities												122,575,000	126,010,000	126,728,000	126,407,000	125,793,000	86,012,000	85,019,719																															56,008	106,500	108,965	78,680	71,828	634,585	1,177,708	2,253,030
current assets
cash and cash equivalents											139,439,000	86,408,000	91,587,000	184,434,000	325,981,000	372,377,000	139,921,000	143,582,667	219,322,617	256,650,727	461,032,249	221,804,128	188,331,747	161,639,208	189,772,981	30,133,213	27,995,386	69,805,117	11,531,345	24,838,567	38,383,135	61,718,971	102,105,569	85,366,448	43,616,543	50,300,847	62,165,088	81,214,354	87,252,813	96,447,301	103,991,231	132,510,610	138,349,733	142,847,860	59,713,424	19,114,444	29,025,930	3,313,483	2,931,032	3,377,288	2,282,641	3,595,112	6,773,126	7,507,389	4,316,308	4,789,599	5,466,804	6,847,162	8,983,445	2,593,044	3,809,596	2,020,224	1,909,185	3,557,340	7,636,842	10,093,585	13,823,480	19,522,301	25,424,317	24,120,097	3,421,278	21,591,701	28,266,834	28,020,304	16,688,051	16,584,747	19,105,345
long term investments											165,920,000	201,590,000	217,572,000	245,595,000	128,376,000	97,490,000	110,855,000	137,486,883	177,529,881	190,618,075	26,329,098		57,555,499	67,536,054	59,595,287		17,672,658
current liabilities
long-term liabilities
arrowhead pharmaceuticals, inc. stockholders’ equity:
total arrowhead pharmaceuticals inc. stockholders' equity											453,927,000
total stockholders’ equity											474,177,000	452,266,000	372,560,000	408,822,000	436,890,000	445,549,000	454,472,000	461,779,132	492,585,205	493,563,470	499,528,643	244,036,252	225,670,040	200,640,236	171,500,031	95,241,001	101,759,359	113,715,082	70,199,310	80,867,162	89,542,284	93,336,489	97,208,421	95,024,259	59,425,166	73,926,237	92,368,392	109,621,634	130,744,394	144,196,354	145,709,671	165,985,255	185,807,789	189,537,557	80,910,287	25,734,789	33,305,968	3,760,504	7,604,479	8,808,909	8,448,603	11,566,686	15,748,910	12,564,168	10,569,252	12,222,075	7,287,812	8,078,296	9,455,819	5,478,569	6,549,475	4,857,936	3,714,023	406,071	5,000,075	12,302,609	13,100,219	19,063,864	23,770,773	26,303,968	33,176,218	24,476,795	30,162,444	30,671,206	37,624,672	41,199,625
liabilities and stockholders’ equity
total liabilities and stockholders’ equity												703,575,000	638,539,000	710,148,000	734,927,000	756,795,000	499,251,000	522,503,743	555,728,072	561,075,702	587,601,634	349,845,437	336,828,445	333,940,433	340,947,388	111,609,951	112,903,027	126,998,915	88,220,493	104,022,280	115,081,549	126,871,643	144,258,106	128,176,505	85,533,496	94,607,471	111,381,139	132,267,914	145,190,325	162,378,458	162,136,761	182,816,756	196,622,876	202,641,394	92,692,477	37,329,631	41,488,495	12,419,325	15,231,131	16,527,818	16,488,027	20,080,976	23,062,344	15,888,563	13,289,834	15,236,725	15,189,763	12,354,542	14,596,070	7,758,203	9,129,264	7,702,174	8,198,650	10,167,700	15,390,124	17,255,442	19,126,157	24,821,967	30,663,734	29,852,952	36,716,378	26,904,512	34,393,825	34,525,878	40,582,772	45,085,271
other current liabilities																17,000	17,000	17,262	17,262	17,263	16,561	16,561				46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	46,407	59,762	65,213	58,495	58,500	60,592	588,343	588,343	546,407	546,407	606,345	1,692,394	1,592,394	106,345
operating lease - right-of-use assets															18,450,000
arrowhead pharmaceuticals, inc. stockholders' equity:
deferred rent																						173,952	173,952	173,952	212,159	307,334	440,580	440,580	440,580	440,580	440,580	440,580	440,580	440,580	2,243,406
deferred rent, net of current portion																						3,703,364	1,812,346	1,754,869	1,664,182	1,702,801	1,657,899	1,744,863	1,834,392	1,929,052	2,016,113	2,102,408	2,188,703	2,274,997
note payable																										223,820	219,889	216,027	212,233	208,506	204,844	201,247	197,713	194,310	144,435																						500,000	500,000	500,000	500,000
note payable, net of current portion																										2,101,198	2,158,649	2,215,091	2,270,542	2,325,018	2,378,538	2,431,118	2,482,775	2,533,455																839,421	793,513	748,104	702,695
other non-current liabilities																										200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	200,000	329,760	336,427	342,453	346,996	350,798	253,321	255,206	1,752,822		1,757,384	1,758,709	337,587	272,179	270,931	269,142	93,731		106,345	135,660
restricted cash																							1,000,000
derivative liabilities																													20,445	695,114	83,113	146,178	118,795	1,602,626	1,068,552	955,193	1,325,128	1,301,604	1,724,468	1,619,755	1,790,559	4,173,943	4,018,719	4,936,530	5,097,442	4,096,363	2,335,163	2,535,910	1,490,584	647,213	869,766	1,643,403	1,010,883	944,980	958,451	1,653,810
preferred stock, 0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of september 30, 2017 and september 30, 2016
preferred stock, 0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of june 30, 2017 and september 30, 2016
preferred stock, 0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of march 31, 2017 and september 30, 2016
trade receivables																																	60,000								127,000
preferred stock, 0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of december 31, 2016 and september 30, 2016
trade receivable																																		75,000											75,000	75,000			115,266	9,375		22,660
capital lease obligation																																			216,653	219,349	218,447	217,548	216,653	215,762	213,991	213,991	213,110	212,234	221,345	221,345	219,690	218,048	216,419	214,801	213,196	211,602	209,555						74,845	296,419
capital lease obligation, net of current portion																																			378,862	430,665	485,842	540,792	595,516	650,014	705,173	758,340	812,169	865,777	1,006,398	1,061,113	1,117,074	1,172,616	1,227,743	1,282,458	1,336,764	1,390,665	1,444,370
contingent consideration obligations																																			5,862,464	5,862,464	5,862,464	5,862,464	3,970,931	3,970,931	3,970,931	3,970,931
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of september 30, 2016 and september 30, 2015																																		16
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of june 30, 2016 and september 30, 2015																																			16
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of march 31, 2016 and september 30, 2015																																				16
arrowhead research corporation stockholders' equity:
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of december 31, 2015 and september 30, 2015																																					16
total arrowhead research corporation stockholders' equity																																					92,923,580	110,176,822	131,299,582	144,751,542	146,264,859	166,540,443	186,362,887	191,399,034	82,731,584	27,498,666									10,625,775
investments																																							1,085,282	12,361,068	17,806,499	23,088,346	26,284,862	34,048,359	9,867,857
notes payable																																										50,000	50,000	1,050,000	1,050,000	971,557	925,649	880,239	935,329												500,000	500,000
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of september 30, 2015 and september 30, 2014, respectively																																						16
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of june 30, 2015 and september 30, 2014, respectively																																							16
due to novartis																																								3,000,000
preferred stock, 0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of march 31, 2015 and september 30, 2014, respectively																																								16
preferred stock, 0.001 par value; 5,000,000 shares authorized; 18,300 and 18,300 shares
issued and outstanding as of december 31, 2014 and september 30, 2014, respectively																																									18
accumulated deficit during the development stage																																									-247,346,441			-190,711,800	-176,769,281	-166,140,969	-152,448,785	-146,369,775	-139,611,839	-134,997,680	-129,683,999	-121,692,489	-116,357,257	-113,871,752	-111,095,229	-109,275,312	-112,180,549	-110,742,867	-108,738,761	-108,367,706	-106,513,746	-104,968,819	-101,344,831	-98,816,214	-93,526,935	-85,496,467	-76,838,188	-69,336,026	-63,641,211	-58,407,437	-50,834,846	-38,357,298	-32,183,489	-28,476,319	-19,696,796	-15,722,648	-12,616,063
notes payable, net of current portion																																														50,000	50,000	50,000	50,000
preferred stock, 0.001 par value; 5,000,000 shares authorized; 18,300 and 9,900 shares issued and outstanding as of september 30, 2014 and september 30, 2013, respectively																																										18
non-controlling interest																																										-555,188	-555,098
patents and other intangible assets																																											3,199,523		3,226,850	3,240,513	3,254,177	4,636,339	4,710,454	4,784,569	4,685,063	2,675,478	2,749,593
preferred stock, 0.001 par value; 5,000,000 shares authorized; 21,291 and 9,900 shares
issued and outstanding as of june 30, 2014 and september 30, 2013, respectively																																											21
issued and outstanding as of march 31, 2014 and september 30, 2013, respectively																																												21
shares issued and outstanding as of march 31, 2014 and september 30, 2013, respectively																																												144,237
other receivables																																													20,488	8,663	267,560		9,305	9,930	677,447	2,306,606	2,027,620	1,608,382	1,349,898	1,267,691	785,709	871,819	727,015	116,382	3,109	3,109	1,983	3,109	3,109	28,109	25,000	2,200	2,200	2,200	229,604	2,200	33,520	70,517		2,200	6,700
prepaid expenses and other current assets																																													689,954	615,351	1,059,503	426,398	460,922	618,130	432,379	456,603	301,334	110,818	204,642	271,062
computers, office equipment and furniture																																													323,376	323,376	323,376	323,376	323,376	323,376	508,613	502,508	502,508	285,266	285,266	281,473	335,784	335,784	374,991	374,991	374,991	374,991	374,991	575,036	575,036	571,616	531,453	629,092	626,339	614,213	590,749	561,986	548,919	544,823	502,912	459,002	400,551
research equipment																																													3,319,429	3,452,013	3,346,789	3,186,601	3,225,540	3,319,027	3,409,693	4,459,820	4,450,087	3,515	3,515	3,515	752,850	752,850	932,683	932,683	932,683	932,683	932,683	1,960,242	2,010,796	1,986,117	1,863,405	2,275,496	2,101,874	1,977,882	1,824,713	1,472,034	1,447,532	1,375,595	1,125,794	991,651	949,016
software																																													69,623	69,623	69,623	69,623	69,623	69,623	105,916	105,916	105,916	77,020	77,020	77,020	150,445	150,445	150,445	150,445	150,445	150,445	150,445	167,615	167,615	167,615	155,315	141,581	133,266	107,128	98,093	68,969	68,969	68,969	52,023	52,023	52,023
leasehold improvements																																													2,749,409	2,749,409	2,749,409	2,749,409	2,749,409	2,749,409	2,762,737	2,749,409	2,591,919			66,448	78,594	78,594	94,317	94,317	94,317	94,317	88,470	115,871	115,871	115,871	121,717	424,968	421,732
less: accumulated depreciation and amortization																																													-3,275,690	-3,081,186	-2,695,886	-2,315,915	-1,941,265	-1,565,783	-1,421,170	-1,072,439	-723,190	-340,364	-335,880	-396,308	-1,219,867	-1,176,404	-1,296,459	-1,214,306	-1,120,790	-1,025,392	-929,229	-1,914,774	-1,775,389	1,596,009	-1,412,188	-2,050,705	-1,857,186	-1,675,998	-1,493,821	-1,345,221	-1,214,692		-972,260	-829,617
total other assets																																													13,094,707	4,972,677	3,284,188	4,666,350	4,740,465	5,064,830	5,219,204	4,518,201	6,961,196	6,001,952	6,211,357	6,623,195	4,051,418	4,081,498	4,214,217	4,429,603	4,549,223	4,691,575	4,826,537	5,086,142	5,275,269	5,449,115	3,325,288	2,854,908	3,029,594	3,108,065	3,181,702	3,243,303	4,326,958	4,479,106	8,162,582	7,974,062	5,335,303
preferred stock, 0.001 par value; 5,000,000 shares authorized; 51,291 and 9,900 shares
issued and outstanding as of december 31, 2013 and september 30, 2013, respectively																																													51
note receivable																																																	2,491,450	2,446,113	2,401,602	2,357,900	2,314,994	2,272,868	2,231,509	2,190,903
derivative asset and other non-current assets																																														1,732,164	30,011	30,011	30,011	280,261
accrued salaries and payroll-related expenses																																														905,771
preferred stock, 0.001 par value; 5,000,000 shares authorized; 9,900 and 0 shares issued and outstanding as of september 30, 2013 and 2012, respectively																																														10
subscription receivable																																																	-1,500,000	-1,016,000	-1,000,000	-2,665,000	-3,897,500	-900,000							-317,000	-300,000
arrowhead research corporation stockholders’ equity:
preferred stock, 0.001 par value; 5,000,000 shares authorized; 9,900 shares issued and outstanding																																															10
total arrowhead research corporation stockholders’ equity																																															34,956,969	5,312,887	8,974,780	10,012,642	9,365,268	12,235,800	16,169,142	12,791,106		12,085,101	8,048,966	9,045,702	10,113,115	5,877,779	6,671,280
preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
investment in nanotope inc., equity basis																																																				1,478,959	1,543,220	1,649,748	1,716,561	1,786,927	1,861,754	1,812,927	1,866,740	1,933,230	1,983,829	2,032,467		2,128,859	2,188,889	2,258,271
investment in leonardo biosystems inc., at cost																																																			187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000	187,000
rent deposit																																																			34,891	6,264	6,264				34,735	34,735	34,735	104,725	94,840	109,648	117,614	228,814	257,809	254,289	137,358	124,376	195,072	169,552	139,187	96,797	113,311	161,469	164,425	183,429	164,049
derivative asset																																																			312,250	170,500	160,125	161,125	284,625	606,250
preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
preferred stock, 0.001 par value; 5,000,000 shares authorized; 1,015 shares issued and outstanding																																																					1
trade receivable, net of allowance for doubtful accounts of 90,789 at september 30, 2010
patents																																																						1,731,211	1,791,662	1,852,115	1,967,929	2,046,836	2,125,742	2,204,648	2,283,554	2,362,460
net property and equipment																																																								32,148	97,806	141,269	255,977	338,130	431,646	527,044	617,360	903,990	1,093,929	1,245,210	1,259,702	1,420,432	1,426,025	1,439,459	1,428,978	1,167,013	1,259,973		1,078,168	997,749
arrowhead research corporation shareholders’ equity:
trade receivable, net of allowance for doubtful accounts of 89,589 at december 31, 2010 and 90,789 at september 30, 2010																																																									4,587,173
accrued severance																																																									23,500	23,500	23,500	23,500	23,500	23,500	23,500	250,000	250,000	250,000	250,000	250,000		495,000
derivative liability																																																									1,943,252	2,408,522	2,617,679
trade receivable, net of allowance for doubtful accounts of 90,789 at september 30, 2010 and 30,789 at september 30, 2009																																																										58,864
trade receivable, net of allowance for doubtful accounts of 90,789 at june 30, 2010 and 30,789 at september 30, 2009																																																											9,464
trade receivable, net of allowance for doubtful accounts of 90,789 at march 31, 2010 and 30,789 at september 30, 2009																																																												55,937
trade receivable, net of allowance for doubtful accounts of 30,789 at december 31, 2009 and september 30, 2009																																																													129,772
other prepaid expenses																																																													205,918	316,074	449,772	451,434	365,616	380,933	535,325	471,101	295,477	409,656	583,971	425,108	199,298	315,653	310,711	329,249	72,469
intangible and other assets
capital lease obligation—short term																																																													513,620
trade receivable, net of allowance for doubtful accounts of 30,789 at september 30, 2009 and 116,031 at september 30, 2008																																																														144,148
grant receivable, net of allowance for doubtful account of 0																																																																50,982	139,669	54,436	37,929	408,570	130,445				3,697	3,697	34,377	40,000	30,000
payroll liabilities																																																														160,846	283,278	310,844	484,838	479,294	609,051	395,290	472,755	407,997	651,494	326,424	369,470	233,932	334,543	210,615	264,986
capital lease obligation - short term																																																														726,534				810,456
capital lease obligation - long term																																																																		726,534
minority interests																																																																			2,970,483	2,964,571	4,109,567	152,609	600,038	1,281,507	3,216,137	934,438	1,229,462	1,296,410	1,092,753
commitment and contingencies
trade receivable, net of allowance for doubtful account of 100,591 at june 30, 2009 and 116,031 at september 30, 2008																																																															393,813
patents, note 1.																																																															2,441,366	2,541,469	2,641,571	2,749,555	2,627,930	2,730,532	2,834,522	2,938,513	3,042,515	3,146,506	3,250,497	3,354,487	3,490,730	3,323,206
investment in nanotope inc., equity basis, note 4.																																																															2,080,557
capital lease obligation—short term, note 10.																																																															860,401	843,420	826,774
notes payable, note 6.																																																															500,000	2,516,467	2,516,467
capital lease obligation—long term, note 10.																																																															74,845	296,419	513,620
accrued severance, note 11.																																																																500,000	500,000
unidym series c-1 preferred stock with liquidation preference and put option, note 7.																																																															500,000	2,000,000	2,000,000
commitment and contingencies, note 11.
stockholders’ equity, note 8.
preferred stock
trade receivable, net of allowance for doubtful account of 116,031 for 2009 and 2008																																																																114,703	116,371
subscription receivable, note 16.																																																																	750,000
prepaid sponsored research, note 11.																																																																	9,319
trade receivable, net of allowance for doubtful account of 116,031 for 2008 and 45,659 for 2007																																																																		4,054
prepaid sponsored research, note 9.
other prepaid research																																																																						278,558	67,646	162,350	1,417	7,600	223,288	234,667	229,167
current assets of discontinued operation, note 5.
property and equipment of discontinued operation
accumulated depreciation and amortization of discontinued operation
non-current assets of discontinued operation
current liabilities of discontinued operation
accrued severance, note 9.																																																																		500,000
commitments and contingencies, note 9.
stockholders’ equity, note 6.
trade receivable, net of allowance for doubtful account of 56,031																																																																			94,427
prepaid sponsored research, note 8.																																																																			25,006
current assets of discontinued operations, note 5.
property and equipment of discontinued operations
minority investment in private company																																																																			560,000
non-current assets of discontinued operations
current liabilities of discontinued operations
accrued severance, note 8.																																																																			500,000
commitment and contingencies, note 8.
trade receivable, net of allowance for doubtful account of 46,031																																																																				83,950	270,546
prepaid sponsored research, note 7.																																																																				58,505	85,130	221,053	271,945
accrued severance, note 7.																																																																				500,000	500,000	500,000
commitment and contingencies, note 7.
stockholders’ equity, note 5.
accounts payable, note 1.																																																																					880,943	1,349,105	1,453,838	490,039	391,611		209,343	1,714,639
accured severance																																																																					495,000
trade receivable, net of allowance for doubtful account of 45,659																																																																						273,864
leasehold improvement																																																																						416,234	409,244	409,245	409,245	369,699	369,699	324,690	324,690
goodwill																																																																									963,150	963,150	4,507,427	4,467,427	1,762,150
preferred stock liability
marketable securities at fair market value - us treasury bills																																																																							27,372,602				13,945,260
trade receivable, net of allowance for doubtful accounts of 13,514																																																																							158,652
grant receivable, net of allowance for doubtful accounts of 0
prepaid sponsored research, note 6.																																																																								312,837	302,128	358,020	138,135	213,487
commitment and contingencies, note 6.
stockholders’ equity, note 4.
investments at fair market value
property & equipment
construction in progress
less: accumulated depreciation & amortization																																																																										-1,088,105			-700,118
net property & equipment																																																																										1,270,981			1,026,162
preferred stock liability, note 11																																																																										1,162,000
stockholders’ equity, par value .001 per share note 4.
other receiviables																																																																											2,200
deferred compensation																																																																											-4,971,396	-3,073,750	-3,207,749
marketable securities at fair market value—us treasury bills																																																																												18,709,110
prepaid sponsored research, note 6																																																																													75,000
patents, note 1																																																																													3,409,104
liabilities and shareholders’ equity
commitment and contingencies, note 6
shareholders’ equity, note 4
total shareholders’ equity																																																																													23,330,891
total liabilities and shareholders’ equity																																																																													25,880,146

We provide you with 20 years of balance sheets for Arrowhead Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arrowhead Pharmaceuticals. Explore the full financial landscape of Arrowhead Pharmaceuticals stock with our expertly curated balance sheets.

The information provided in this report about Arrowhead Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.